Sign in
CompletedEarly phase 1

Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease

Key facts

Who runs it
University of Pennsylvania
Where
Philadelphia, United StatesSee the site
Trial code
Status
Completed
Phase
Early phase 1
People taking part
24 people enrolled
Started
25 Sept 2024
Ended
25 Mar 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Colchicine
  • Placebo
Record updated
2 April 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age >= 18 years
  • Diagnosis of peripheral artery disease
  • Stated willingness to comply with all study procedures and availability for the duration of the study

Who cannot take part

  • Use of colchicine or systemic anti-inflammatory medication (eg. tocilizumab) in the past 3 months
  • Presence of medication with drug-drug interaction
  • Recent (<14 days) systemic infection requiring hospitalization or ongoing treatment with antimicrobials
  • History of uncontrolled diabetes or an A1C >10% prior to the baseline visit
  • Allergy to colchicine
  • Autoimmune/autoinflammatory disorders affecting blood vessels or with planned need for systemic anti-inflammatory medication
  • History of persistent anemia, thrombocytopenia, or neutropenia requiring hematology/oncology treatment or felt to pose unacceptable risk to colchicine by the principal investigator
  • History of CrCl < 30 mL/minute or eGFR < 30mL/minute or end-stage renal disease ESRD on dialysis
  • History of liver disease or chronically-elevated (>3 months) ALT/AST > 3.0 x ULN
  • Acute limb ischemia requiring emergent intervention
  • Pregnant or lactating women
  • Claustrophobia

Where in United States

  • University of PennsylvaniaPhiladelphia, United States

About the trial

What the trial wants to find out

The goal of this mechanistic clinical trial is to test the effects of reducing inflammatory signaling in femoral artery atherosclerotic plaques. Researchers will compare patients receiving colchicine to patients receiving placebo to determine the effect of colchicine on the inflammatory state of atherosclerotic femoral arteries.

The 2 groups in the trial

  • ColchicineTreatment being tested

    Colchicine (0.6 mg oral daily for 4-weeks) will be the drug administered in this study.

  • PlaceboPlacebo, for comparison

    This arm is a matching placebo that will be administered in the same fashion as the experimental arm.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Placebo-Controlled Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease
Record updated
2 April 2026